Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

Condition:   BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer Intervention:   Drug: Olaparib tablets Sponsor:   National Cancer Institute, Naples Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials